Status:
TERMINATED
Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children
Lead Sponsor:
Children's Hospital of Fudan University
Collaborating Sponsors:
RenJi Hospital
Shanghai Children's Hospital
Conditions:
COVID-19
Children
Eligibility:
All Genders
12-18 years
Phase:
PHASE1
PHASE2
Brief Summary
In the COVID-19 pandemic era, a convenient and effective treatment for pediatric patients is unavailable. A multi-center Chinese clinical trials with the aim to using Interferon-α2b spray inhalation t...
Detailed Description
This project aims to improve the treatment of pediatric patients infected with COVID-19. Interferon has antiviral property and is approved to be used in treatment in hepatitis B and hepatitis C virus ...
Eligibility Criteria
Inclusion
- Patients diagnosed as mild to moderate COVID-19 infection with positive PCR test and symptoms (Ct \< 35)
- Parents and patients comprehend and welling to participate in this study.
- Agree to the collection of nasal swabs per day as protocol.
Exclusion
- Patients evaluated as severe or critically severe type of COVID-19 infection (Individuals who have SpO2 \<94% on room air, oxygen treatment is necessary, respiratory failure, septic shock, and/or multiple organ dysfunction).
- Patients with comorbidities
- Decline to participate by parents or children
- Allergy to any study medication or usage of any kind of interferon treatment within 14 days before test
- Children cannot tolerate the inhalation treatment
- Any situation where the program cannot be carried out safely.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2023
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT05381363
Start Date
January 1 2022
End Date
January 1 2023
Last Update
December 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children Hospital of Fudan University
Shanghai, China, 201102